Almac has purchased and installed an llumina NovaSeq X Plus instrument in Northern Ireland, which is set to expand its next generation sequencing capabilities for BioPharma partners
Almac Diagnostic Services, a member of the Almac Group, is set to expand its next generation sequencing (NGS) capabilities for BioPharma partners, following the purchase and installation of the first Illumina NovaSeq X Plus instrument in Northern Ireland and the whole island of Ireland.
This investment in the newest and most powerful instrument from Illumina enhances Almac’s NGS portfolio of DNA Sequencing Service offerings, including Whole Genome Sequencing, Whole Exome Sequencing and a range of RNA Sequencing Service offerings for Biomarker Discovery projects.
Adding the Illumina NovaSeq X Plus’s powerful processing capabilities to Almac’s existing range of NGS platform offerings will enable even larger sample runs, greater read depth, including both short and long-read sequencing and faster speeds.
As a result, it will increase throughput, variant detection quality and accuracy, while reducing turnaround time and cost per sample for client biomarker research projects.
Almac has a record for excellence in precision medicine and we are delighted to be an important strategic partner
- Mark Robinson, General Manager, UK and Ireland, Illumina
Michael Sloan, Global VP of Commercial Operations, Almac Diagnostic Services said: “Investing in this new instrument further enhances our DNA and RNA panel offerings, opens the potential for further expansion of our NGS solutions for clients and significantly increases overall sequencing capacity.”
Almac Group has committed to achieving net zero by 2045 and to reducing Scope one and Scope two emissions by 50 percent by 2030. Illumina’s focus on sequencing sustainability to reduce impact on the environment aligns with this commitment.
The NovaSeq X Plus has 90% less packaging weight and waste, new compact cartridges and packaging design and more recyclable plastics which helps to save on disposal costs and environmental impact.
"Almac has a record for excellence in precision medicine and we are delighted to be an important strategic partner," said Mark Robinson, General Manager, UK and Ireland, Illumina.